Inclusion Criteria:

          -  The patient or a legally authorized representative must provide study-specific
             informed consent prior to study entry.

          -  Age ≥ 18 years of age.

          -  Karnofsky performance status (KPS) of ≥ 70%.

          -  Subjects with either 1) non-metastatic biopsy proven adenocarcinoma of the prostate
             who have chosen AS the treatment option for their prostate cancer or 2) have the
             diagnosis of either MGUS or low-risk SMM and are currently on observation alone.

          -  For patients with MGUS or low-risk SMM, diagnosis must be according to the definition
             of the International Myeloma Working Group (IMWG).

               1. MGUS: serum M-protein <3.0g/dL, <10% clonal plasma cells (PCs) in the bone
                  marrow, and absence of end-organ damage (CRAB criteria) that can be attributed to
                  the plasma cell disorder.

               2. SMM: serum M-protein of ≥3.0g/dL or a proportion of clonal PCs in the BM of ≥10%
                  but <60%, and no evidence of end organ damage as described below.

                    -  Absence of end organ damage is defined by absence of CRAB criteria:

                         -  C: Absence of hypercalcemia, defined as calcium ≤11mg/dL.

                         -  R: Absence of renal failure, defined as serum creatinine ≤2.0mg/dL.

                         -  A: Absence of anemia, defined as hemoglobin ≥10g/dL.

                         -  B: Absence of lytic bone lesions per IMWG recommendations: One of
                            either PET-CT, low-dose whole-body CT, or whole- body MRI. Increased
                            uptake on PET-CT alone is not adequate for the diagnosis of multiple
                            myeloma; evidence of underlying osteolytic bone destruction is needed
                            on the CT portion of the examination.

          -  At least one of the risk factors below that portends for an increased risk of
             progression to MM:

               -  Abnormal serum free light chain ratio.

               -  M-spike ≥2.0g/dL.

               -  ≥ 20% bone marrow clonal plasma cells.

               -  Immunoparesis ≥20% reduction from institutional normal standard of uninvolved
                  immunoglobulins.

        Exclusion Criteria

          -  Currently taking supplements containing either curcumin or piperine.

          -  Plan to start any additional over the counter supplements prior to or during trial
             period.

          -  For prostate cancer patients must not be planning to undergoing primary curative
             therapy for their prostate cancer (radiation, surgery, brachytherapy).

          -  For MGUS/ SMM patients, must not have had evidence of disease progression which might
             require treatment during the one-year study period.

          -  Other: symptomatic plasma cell leukemia, amyloidosis, POEMS syndrome (polyneuropathy,
             organomegaly, endocrinopathy, monoclonal protein).

          -  Subject is pregnant or breast feeding, or planning to become pregnant during the
             treatment period.

          -  Evidence of any of the following conditions per subject self-report or medical chart
             review: Major surgery or significant traumatic injury occurring within 4 weeks before
             enrollment.